APIM Therapeutics announced today that Columbia University (CU) will be presenting a clinical-trial-in-progress poster at the ASCO annual meeting showing the design of their phase 2 study with our lead compound ATX-101. APIM supports this investigator sponsored clinical trial in patients suffering from lipo- and leiomyosarcoma. This is the second ongoing clinical phase 2 study with ATX-101.The poster presentation can be visited in Hall A starting at 8:00am (abstract #: TPS11587; poster BD #: 488b, see also here).
